Who are Chlorhexidine gluconate (4%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chlorhexidine 0.2%, Curasept, Topical Hydrogen Peroxide, chlorhexidine digluconate, Chlorhexidine Gluconate (CHG), B (Clorhexidine 2%), The Chlorhexidine gluconate 0.05%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chlorhexidine-gluconate-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chlorhexidine gluconate (4%) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlorhexidine gluconate (4%) (Chlorhexidine gluconate (4%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial agent / Antiseptic. Area: Infectious Disease / Antisepsis.

marketed Antimicrobial agent / Antiseptic Infectious Disease / Antisepsis Small molecule Live · refreshed every 30 min

Target snapshot

Chlorhexidine gluconate (4%) (Chlorhexidine gluconate (4%)) — The Cooper Health System. Chlorhexidine gluconate is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Chlorhexidine gluconate (4%) TARGET	Chlorhexidine gluconate (4%)	The Cooper Health System	marketed	Antimicrobial agent / Antiseptic
Chlorhexidine 0.2%, Curasept	Chlorhexidine 0.2%, Curasept	University of Oslo	marketed	Antimicrobial agent / Antiseptic
Topical Hydrogen Peroxide	Topical Hydrogen Peroxide	University of Toronto	marketed	Antimicrobial agent / Antiseptic
chlorhexidine digluconate	chlorhexidine digluconate	Universidade Federal do Ceara	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
Chlorhexidine Gluconate (CHG)	Chlorhexidine Gluconate (CHG)	University of Pennsylvania	marketed	Antimicrobial agent / Antiseptic
B (Clorhexidine 2%)	B (Clorhexidine 2%)	Instituto de Investigacion Sanitaria La Fe	marketed	Antimicrobial agent / Antiseptic
The Chlorhexidine gluconate 0.05%	The Chlorhexidine gluconate 0.05%	HaEmek Medical Center, Israel	marketed	Antimicrobial agent / Antiseptic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial agent / Antiseptic class)

Universidad de Guanajuato · 2 drugs in this class
University of Oslo · 2 drugs in this class
Johns Hopkins University · 1 drug in this class
The Cooper Health System · 1 drug in this class
Universidade Federal do Ceara · 1 drug in this class
University of Milan · 1 drug in this class
University of Pavia · 1 drug in this class
University of Pennsylvania · 1 drug in this class
University of Santiago de Compostela · 1 drug in this class
HaEmek Medical Center, Israel · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chlorhexidine gluconate (4%) — Competitive Intelligence Brief. https://druglandscape.com/ci/chlorhexidine-gluconate-4. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing